Updated safety analysis of cladribine tablets in the treatment of patients with multiple sclerosis

被引：0
|
作者：
Cook, S. [1 ]
Giovannoni, G. [2 ]
Leist, T. [3 ]
Syed, S. [4 ]
Nolting, A. [5 ]
Schick, R. [5 ]
机构：
[1] Rutgers State Univ, New Jersey Med Sch, Newark, NJ USA
[2] Queen Mary Univ London, Blizard Inst, Barts & London Sch Med & Dent, London, England
[3] Thomas Jefferson Univ, Jefferson Med Coll, Div Clin Neuroimmunol, Philadelphia, PA 19107 USA
[4] EMD Serono Inc, Billerica, MA USA
[5] Merck KGaA, Darmstadt, Germany
来源：
MULTIPLE SCLEROSIS JOURNAL | 2018年 / 24卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P875
引用
收藏
页码：465 / 466
页数：2
相关论文
共 50 条
  • [41] AN ANALYSIS OF MALIGNANCY RISK IN THE CLINICAL DEVELOPMENT PROGRAMME OF CLADRIBINE TABLETS IN PATIENTS WITH RELAPSING MULTIPLE SCLEROSIS
    Galazka, Andrew
    Nolting, Axel
    Cook, Stuart
    Leist, Thomas
    Comi, Giancarlo
    Montalban, Xavier
    Hicking, Christine
    King, John
    Dangond, Fernando
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2018, 89 (06): : E17 - E17
  • [42] Effects of cladribine tablets on lymphocyte subsets in patients with multiple sclerosis: an extended analysis of surface markers
    Stuve, Olaf
    Soerensen, Per Soelberg
    Leist, Thomas
    Giovannoni, Gavin
    Hyvert, Yann
    Damian, Doris
    Dangond, Fernando
    Boschert, Ursula
    THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2019, 12
  • [43] Clinical development plan for cladribine tablets, an oral immunomodulator, for the treatment of multiple sclerosis
    Viglietta, V.
    Greenberg, S.
    Mikol, D.
    Weiner, J.
    Alteri, E.
    Chang, P.
    Krumwieh, D.
    Musch, B.
    MULTIPLE SCLEROSIS, 2009, 15 (09): : S126 - S126
  • [44] Correction: Expert Narrative Review of the Safety of Cladribine Tablets for the Management of Relapsing Multiple Sclerosis
    Pierre Clavelou
    Giovanni Castelnovo
    Valérie Pourcher
    Jerome De Sèze
    Patrick Vermersch
    Ali-Frederic Ben-Amor
    Carine Savarin
    Gilles Defer
    Neurology and Therapy, 2024, 13 : 255 - 256
  • [45] European experience of cladribine tablets in elderly multiple sclerosis: Could it be the last treatment ?
    de Seze, Jerome
    Zecca, Chiara
    Castelnovo, Giovanni
    Ayrignac, Xavier
    Patrick, Vermersch
    Gobbi, Claudio
    Claudia, Mallucci
    Dalliere, Clarisse Carra
    Pierre, Labauge
    Bigaut, Kevin
    Laurent, Kremer
    Collongues, Nicolas
    Lanotte, Livia
    Thouvenot, Eric
    Ernon, Christine
    Dive, Dominique
    MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (03) : 344 - 345
  • [46] Late stage clinical development plan for cladribine tablets in the treatment of multiple sclerosis
    Viglietta, V.
    Greenberg, S.
    Mikol, D.
    Weiner, J.
    Alteri, E.
    Chang, P.
    Krumwieh, D.
    Musch, B.
    JOURNAL OF NEUROLOGY, 2010, 257 : S143 - S144
  • [47] Danish experience with cladribine tablets in the treatment of relapsing multiple sclerosis: a nationwide study
    Sorensen, P. S.
    Heick, A.
    Petersen, T.
    Joensen, H.
    Kopp, T. I.
    Sellebjerg, F.
    Magyari, M.
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 165 - 165
  • [48] Recommendations for the use of cladribine tablets in recurring multiple sclerosis
    Oreja-Guevara, Celia
    Garcia-Merino, Juan A.
    Saiz, Albert
    Rodriguez-Antiguedad, Alfredo
    Alvarez-Cermeno, Jose C.
    Estrada-Perez, Vicente
    Izquierdo, Guillermo
    Fernandez, Oscar
    REVISTA DE NEUROLOGIA, 2019, 69 : S1 - S9
  • [49] COST-EFFECTIVENESS OF CLADRIBINE TABLETS IN THE TREATMENT OF PATIENTS WITH HIGHLY ACTIVE RELAPSING MULTIPLE SCLEROSIS IN PORTUGAL
    Pinheiro, B. A.
    Guerreiro, R.
    Costa, J.
    Silva Miguel, L.
    VALUE IN HEALTH, 2018, 21 : S339 - S339
  • [50] Cladribine tablets and multiple sclerosis: NICE technology appraisal
    Gaber, Tarek
    Shippen, Clare
    PROGRESS IN NEUROLOGY AND PSYCHIATRY, 2018, 22 (01) : 5 - 6
12345